Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.30 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24156584 | 1.00 | BRPF1 (0.46) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24157395 | 0.82 | BRPF1 (0.47) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL30212596 | 0.82 | BRPF1 (0.47) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL15231700 | 0.81 | CREBBP (0.46) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24157211 | 0.81 | BRPF1 (0.46) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24157277 | 0.80 | MGAT2 (0.34) | CREBBPBRD4 | |
| SCHEMBL31049730 | 0.80 | BRPF1 (0.42) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL25377725 | 0.80 | BRPF1 (0.42) | BRPF1CREBBPGSK3BPOLBTSHR | |
| SCHEMBL24156604 | 0.80 | GAA (0.38) | MEN1KMT2A | |
| SCHEMBL30212563 | 0.80 | MGAT2 (0.34) | CREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094958-A | PARP1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122059929-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122036687-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036686-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122010903-A | Quinoxaline derivatives as anticancer agents | 阿斯利康(瑞典)有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025090418-A1 | PARP1 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-119431314-A | Substituted nitrogen-containing bicyclic compounds and uses thereof | 广东东阳光药业股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-119365457-A | Compounds having PARP1 inhibitory activity and uses thereof | 上海海和药物研究开发股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-4452256-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | Astrazeneca AB (SE) | 2024-10-30 | — | — | EP | disclosed |
| CN-118496203-A | Quinoxaline compound and medical application thereof | 苏州隆博泰药业有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118317793-A | Methods for treating brain tumors and neuroblastomas | 阿斯利康(瑞典)有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024097775-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-117946074-A | Compounds having PARP1 inhibitory activity and uses thereof | 上海海和药物研究开发股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117447449-A | PARP1 inhibitor and application thereof | 南京圣和药业股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023118085-A1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2023-06-29 | — | — | WO | disclosed |
| EP-4172152-A1 | QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS | Astrazeneca AB (SE) | 2023-05-03 | — | — | EP | disclosed |
| WO-2023046149-A1 | QUINOXALINE COMPOUND AND MEDICINAL USE THEREOF | 张文燕 | 2023-03-30 | — | — | WO | disclosed |
| CN-115768760-A | Quinoxaline derivatives as anti-cancer agents | 阿斯利康(瑞典)有限公司 | 2023-03-07 | — | — | CN | disclosed |